Noriyoshi Iriyama 研究室

AI 要約（直近 5 年の研究成果）

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

研究成果（40 件）

• [2026] Additional file 1 of Geriatric assessment-based therapy for older patients with diffuse large B-cell lymphoma: results of a two-decade clinical experience
  DOI: https://doi.org/10.6084/m9.figshare.32622181.v1
• [2026] Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan
  DOI: https://doi.org/10.1007/s12185-026-04184-4
• [2026] Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the <scp>Japan Adult Leukemia Study Group RE</scp> ‐ <scp>STOP219</scp> study
  DOI: https://doi.org/10.1111/bjh.70678
• [2026] Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML
  DOI: https://doi.org/10.1182/bloodadvances.2026020915
• [2026] Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs
  DOI: https://doi.org/10.1182/bloodadvances.2026019701
• [2026] Geriatric assessment-based therapy for older patients with diffuse large B-cell lymphoma: results of a two-decade clinical experience
  DOI: https://doi.org/10.1186/s12885-026-16039-6
• [2026] Additional file 1 of Geriatric assessment-based therapy for older patients with diffuse large B-cell lymphoma: results of a two-decade clinical experience
  DOI: https://doi.org/10.6084/m9.figshare.32622181
• [2025] The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
  DOI: https://doi.org/10.1186/s40959-025-00366-x
• [2025] Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database
  DOI: https://doi.org/10.1007/s12185-025-04069-y
• [2025] The outcome of patients with peripheral T cell lymphoma treated with doxorubicin-based (CHOP) and pirarubicin-based regimen (THP-COP) regimen: a single institution experience
  DOI: https://doi.org/10.3960/jslrt.25010

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。